Skip to main
  1. Stocks
  2. OrthoPediatrics
  3. Forecast
KIDS

OrthoPediatrics (KIDS) Stock Forecast & Price Target

OrthoPediatrics (KIDS) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 13%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

OrthoPediatrics is benefiting from a powerful new-product super cycle and continued share gains in an underpenetrated pediatric orthopedics market, as 3Q26 revenue rose 18.6% to $72.7 million and beat expectations by about 6% while Trauma & Deformity and Scoliosis both posted strong growth. Management’s raised FY26 sales guide of $270 million to $273 million, alongside reaffirmed adjusted EBITDA of $25 million and expected free cash flow breakeven for 2026, suggests operating leverage is building even as launch investments and compensation timing temporarily weighed on EBITDA. With higher-ASP products like 3P Hip and VerteGlide starting to contribute, broader commercial availability expected to expand, and positive free cash flow from 2027 onwards, the company appears positioned for sustained top-line growth and improving profitability.

Bears say

OrthoPediatrics is viewed negatively because its growth depends on successfully converting current and new products into revenue, yet there is a meaningful risk that share gains will be smaller than expected and that margin expansion will fall short. Competition from both large established healthcare companies and smaller entrants with differentiated technology could limit market share gains and create pricing pressure, while the concentrated end market heightens vulnerability to quarterly volatility from disruptions or procedural slowdowns at key accounts. In addition, acquisition and integration risk from continued M&A and liquidity risk add financial uncertainty, making the company’s execution profile fragile.

OrthoPediatrics (KIDS) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OrthoPediatrics and is not a guaranteed prediction by Public.com or investment advice.

OrthoPediatrics (KIDS) Analyst Forecast & Price Prediction

Get the latest OrthoPediatrics (KIDS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in OrthoPediatrics (KIDS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OrthoPediatrics (KIDS) Forecast

Analysts have given OrthoPediatrics (KIDS) a Strong Buy based on their latest research and market trends.

According to 8 analysts, OrthoPediatrics (KIDS) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OrthoPediatrics (KIDS)


OrthoPediatrics (KIDS) Analyst Forecast & Price Prediction

Get the latest OrthoPediatrics (KIDS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in OrthoPediatrics (KIDS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover KIDS stock data and trends